Pneumococcal Nasopharyngeal Carriage following Reduced Doses of a 7-Valent Pneumococcal Conjugate Vaccine and a 23-Valent Pneumococcal Polysaccharide Vaccine Booster
- 1 December 2010
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 17 (12), 1970-1976
- https://doi.org/10.1128/cvi.00117-10
Abstract
This study was conducted to evaluate the effect of a reduced-dose 7-valent pneumococcal conjugate vaccine (PCV) primary series followed by a 23-valent pneumococcal polysaccharide vaccine (23vPPS) booster on nasopharyngeal (NP) pneumococcal carriage. For this purpose, Fijian infants aged 6 weeks were randomized to receive 0, 1, 2, or 3 PCV doses. Within each group, half received 23vPPS at 12 months. NP swabs were taken at 6, 9, 12, and 17 months and were cultured for Streptococcus pneumoniae. Isolates were serotyped by multiplex PCR and a reverse line blot assay. There were no significant differences in PCV vaccine type (VT) carriage between the 3- and 2-dose groups at 12 months. NP VT carriage was significantly higher ( P , <0.01) in the unvaccinated group than in the 3-dose group at the age of 9 months. There appeared to be a PCV dose effect in the cumulative proportion of infants carrying the VT, with less VT carriage occurring with more doses of PCV. Non-PCV serotype (NVT) carriage rates were similar for all PCV groups. When groups were pooled by receipt or nonreceipt of 23vPPS at 12 months, there were no differences in pneumococcal, VT, or NVT carriage rates between the 2 groups at the age of 17 months. In conclusion, there appeared to be a PCV dose effect on VT carriage, with less VT carriage occurring with more doses of PCV. By the age of 17 months, NVT carriage rates were similar for all groups. 23vPPS had no impact on carriage, despite the substantial boosts in antibody levels.This publication has 47 references indexed in Scilit:
- Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trialVaccine, 2010
- Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancyVaccine, 2010
- Nasopharyngeal Carriage of Streptococcus pneumoniae in Gambian Children who Participated in a 9-valent Pneumococcal Conjugate Vaccine Trial and in Their Younger SiblingsThe Pediatric Infectious Disease Journal, 2009
- Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimatesThe Lancet, 2009
- Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccineVaccine, 2009
- Effects of Routine Infant Vaccination With the 7-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization With Streptococcus pneumoniae in Children in Calgary, CanadaThe Pediatric Infectious Disease Journal, 2008
- Strain Characteristics ofStreptococcus pneumoniaeCarriage and Invasive Disease Isolates during a Cluster‐Randomized Clinical Trial of the 7‐Valent Pneumococcal Conjugate VaccineThe Journal of Infectious Diseases, 2007
- Identification of Less-Common Streptococcus pneumoniae Serotypes by a Multiplex PCR-Based Reverse Line Blot Hybridization AssayJournal of Clinical Microbiology, 2007
- Invasive Pneumococcal Disease Caused by Nonvaccine Serotypes Among Alaska Native Children With High Levels of 7-Valent Pneumococcal Conjugate Vaccine CoverageJAMA, 2007
- Multiplex PCR-Based Reverse Line Blot Hybridization Assay To Identify 23 Streptococcus pneumoniae Polysaccharide Vaccine SerotypesJournal of Clinical Microbiology, 2006